Bimekizumab
- Status:
- Red
- Decision Date:
- October 2021
Comments
RED:
- NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis.
- NICE TA916: Bimekizumab for treating active psoriatic arthritis. ICB commissioned (decision date November 2023)
- NICE TA918: Bimekizumab for treating axial spondyloarthritis. ICB commissioned (decision date November 2023)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again